#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Chen W. Liaw and I-Lin Lin Confirmation No.: 5835

Serial No.: 10/782,596 Art Unit No.: 1646

Filing Date: February 19, 2004 Examiner: Ruixiang Li

For: NUCLEIC ACID ENCODING HUMAN G PROTEIN-COUPLED RECEPTOR

Customer No.: 35133

MAIL STOP AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

VIA EXPRESS MAIL LABEL NO: EV770 975 312US

DATE SENT: February 22, 2006

Dear Sir:

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

### This Supplemental Information Disclosure Statement is being filed:

	within three months of the filing date of the patent application.
	within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
$\boxtimes$	before the mailing date of a first Office Action on the merits.
	before the mailing date of a first Office Action on the merits or with the filing of a Request for Continued Examination under § 1.114.

# DOCKET NO: AREN11.US12.CON - 2 - PATENT SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT DATED FEB. 22, 2006

	date o	the mailing date of a first Office Action on the merits, but before the mailing of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance 37 C.F.R. § 1.311, and accordingly is accompanied by:	
		the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below); or	
		the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or	
		No fee is owed by the applicant(s).	
	In accordance with 37 C.F.R. § 1.129(a), this Supplemental Information Disclosure Statement is being filed in connection with the first or second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.		
	after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously with, the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), and the Fee of \$180.00 set forth in 37 C.F.R. §1.17(p).		
$\boxtimes$	-	s of references (except the U.S. Patent documents) listed on the attached Forms SB/08A and SB/08B, formerly known as PTO Form 1449, are sed.	
	EXC	EPT THAT:	
		In view of the voluminous nature of references, and the likelihood that these reference are available to the Examiner, copies are not enclosed herewith.	
		In accordance with 37 C.F.R. § 1.98(d), copies of the references A35 and A37 on the attached PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application no. 09/417,044 for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.	
		If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.	
State	ment ui	nder 37 C.F.R. § 1.97(e)	
	The undersigned attorney hereby states that each item information contained in the Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.		

## DOCKET NO: AREN11.US12.CON - 3 - PATENT SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT DATED FEB. 22, 2006

Staten	nent under 37 C.F.R. § 1.704(d)
	The undersigned attorney hereby states that each item of information contained in the Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and the communication was not received by any individual designated in §1.56(c) more than 30 days prior to the filing of the Supplemental Information Disclosure Statement.
Fees	
$\boxtimes$	No Fee is owed by the applicant(s).
	The Supplemental Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.
	The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.
Metho	od of Payment of Fees
	Attached is a check in the amount of \$ This form is submitted in duplicate.
	Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
	Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
$\boxtimes$	No fee or Statement is required under 37 C.F.R. § 1.97(b) as no first Office Action on the merits has been received by Applicants.
	Respectfully submitted,

COZEN O'CONNOR

Michael A. Patané

Registration No. 42,982

COZEN O'CONNOR 1900 Market Street, 5<sup>th</sup> Floor

Date: Feb. 22, 2006

Philadelphia, PA 19103-3508

Tel:215-665-6966 Fax: 215-701-2080

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Stitute for form 1449A/PTO

SATATIAL .

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known			
Application Number	10/782,596		
Filing Date	February 19, 2004	***	
First Named Inventor	Chen Liaw		
Art Unit	1646		
Examiner Name	Ruixiang Li		
Attorney Docket Number	AREN11.US12.CON		

	U.S. PATENT DOCUMENTS						
Examiner Cite		Cite Document Number	Publication/Issue Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant		
Initials *	No.1	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear		
	A30	US-5,462,856	10-31-1995	Lerner et al.			
	A31	US-6,051,386	04-18-2000	Lerner et al.			
		US-					
		US-					
-		US-					
		US-					
		US-					
		US-					
		US-					
		US-		-	-		
		US-					
		US-					
		US-			-		
		US-					
		US-					
		US-					
	1	US-					

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cito	Foreign Patent Document	D. H. C. C. C. D. A. W. C. C.		Pages, Columns, Lines, Where Relevant		
	Cite No. 1  Country Code 3 - Number 4 - Kind Code 5 (if known)  Publication Date/Filling Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Passages or Relevant Figures Appear	T <sup>6</sup>			
						·	
				<del>-</del>			

Examiner Signature	Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE ct of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 14405

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet of

Complete if Known				
Application Number	10/782,596			
Filing Date	February 19, 2004			
First Named Inventor	Chen Liaw			
Art Unit	1646			
Examiner Name	Ruixiang Li			
Attorney Docket Number	AREN11.US12.CON			

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	A32	Gracheck et al., Annual Rep. Med. Chem. (1993) 28:161-166.		
	A33	Major et al. "Challenges of high throughput screening against cell surface receptors," J. of Receptor and Signal Transduction Res. (1995) 15:595-607.		
	A34	Jayawickreme et al. "Gene expression systems in the development of high-throughput screens," Current Opinion in Biotechnology (1997) 629-634.		
	A35	Ji et al., "G Protein-Coupled Receptors," J. Biol. Chem. (1998) 273:17299-17302.	=	
	A36	Smith et al., Assays of Cycle Nucleotides: A Review of Current Techniques, App. Biochem Biotechnol (1993) 41:189-218.		
	A37	Murdoch et al., "Chemokine receptors and their role in inflammation and infectious diseases," <i>Blood</i> (2000) 95:3032-3043.		

		<del></del>
Examiner	Date	
Signature	Considered	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents P.O. Box 1450, Alexandria VA 22313-150. FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.